Hikma Pharmaceuticals HIK.L · GBp

Its shares trade on LSE under the ticker HIK.L. It has been listed since 1 November 2005. In the fiscal year to 31 December 2025, it reported revenue of $3.35bn and net income of $410.4m. At that date it held total assets of $5.67bn and shareholders' equity of $2.59bn.

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. The firm is focused on developing, manufacturing and marketing a range of both branded and non-branded generic and in-licensed products. The firm's segments include Branded, Injectables, Generics and Others. The company sells branded generics and in-licensed patented products across the Middle East and North Africa (MENA) region and other markets. The firm sells specialized generic injectable products across the globe. The company also sells non-injectable generic products in the United States, supplying over 300 products in different dosage strengths and forms. The firm's other businesses comprise Arab Medical Containers, a manufacturer of plastic specialized medicinal sterile containers, International Pharmaceuticals Research Centre, which conducts bio-equivalency studies, and the active pharmaceutical ingredient (API) manufacturing division of Hikma Pharmaceuticals Limited Jordan.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Said DarwazahExecutive Chairman of the Board, since 2007$3.5m
• Mr. Riad MishlawiChief Executive Officer, Executive Director, since 2011$3.5m
• Mr. Mazen DarwazahExecutive Vice Chairman of the Board, President of MENA, since 2005$2.9m
• Mr. Khalid NabilsiChief Financial Officer
• Dr. Hafrun FridriksdottirPresident - Generics
• Dr. Bill LarkinsPresident - Injectables
• Mr. Hussein ArkhaghaChief People Officer
• Ms. Susan RingdalExecutive Vice President - Strategic Planning and Global Affairs
• Mr. Bassam Wael Roshdi KanaanExecutive Vice President - Corporate Development and M and A, since 2018
• Ms. Julie HillSenior Vice President - Corporate Quality Compliance and Health and Safety
• Ms. Helen MiddlemistCompany Secretary
• Mr. Ali Al-HusryNon-Executive Director$116,961

Overall

68

Environment

41

Social

77

Governance

87

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.